552 related articles for article (PubMed ID: 17940007)
1. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.
DiFiglia M; Sena-Esteves M; Chase K; Sapp E; Pfister E; Sass M; Yoder J; Reeves P; Pandey RK; Rajeev KG; Manoharan M; Sah DW; Zamore PD; Aronin N
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17204-9. PubMed ID: 17940007
[TBL] [Abstract][Full Text] [Related]
2. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
Stanek LM; Sardi SP; Mastis B; Richards AR; Treleaven CM; Taksir T; Misra K; Cheng SH; Shihabuddin LS
Hum Gene Ther; 2014 May; 25(5):461-74. PubMed ID: 24484067
[TBL] [Abstract][Full Text] [Related]
3. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
4. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
[TBL] [Abstract][Full Text] [Related]
5. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells.
Drouet V; Ruiz M; Zala D; Feyeux M; Auregan G; Cambon K; Troquier L; Carpentier J; Aubert S; Merienne N; Bourgois-Rocha F; Hassig R; Rey M; Dufour N; Saudou F; Perrier AL; Hantraye P; Déglon N
PLoS One; 2014; 9(6):e99341. PubMed ID: 24926995
[TBL] [Abstract][Full Text] [Related]
6. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo.
Huang B; Schiefer J; Sass C; Landwehrmeyer GB; Kosinski CM; Kochanek S
Hum Gene Ther; 2007 Apr; 18(4):303-11. PubMed ID: 17472569
[TBL] [Abstract][Full Text] [Related]
7. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
[TBL] [Abstract][Full Text] [Related]
9. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
10. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
[TBL] [Abstract][Full Text] [Related]
11. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
[TBL] [Abstract][Full Text] [Related]
12. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
13. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
Boudreau RL; McBride JL; Martins I; Shen S; Xing Y; Carter BJ; Davidson BL
Mol Ther; 2009 Jun; 17(6):1053-63. PubMed ID: 19240687
[TBL] [Abstract][Full Text] [Related]
14. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.
Franich NR; Fitzsimons HL; Fong DM; Klugmann M; During MJ; Young D
Mol Ther; 2008 May; 16(5):947-56. PubMed ID: 18388917
[TBL] [Abstract][Full Text] [Related]
15. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
17. Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice.
Zheng S; Clabough EB; Sarkar S; Futter M; Rubinsztein DC; Zeitlin SO
PLoS Genet; 2010 Feb; 6(2):e1000838. PubMed ID: 20140187
[TBL] [Abstract][Full Text] [Related]
18. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
[TBL] [Abstract][Full Text] [Related]
19. Sustained effects of nonallele-specific Huntingtin silencing.
Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
[TBL] [Abstract][Full Text] [Related]
20. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]